Stock vs Stock Comparison

Definium Therapeutics, Inc. vs AbCellera Biologics Inc.

ABCL wins the Tale of the Tape 4–1.

DFTX$46.55
ABCL

🏆 Tale of the Tape

14
DFTXABCL
Profitability (Net Margin)-194.9%
-37.7%Efficiency (ROIC)-12.4%
1/9Health (Piotroski F)4/9
Growth (Rev YoY)160.6%
0.32xBalance Sheet (D/E)0.40x

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Fundamentals

MetricDFTXABCL
Market Cap
P/E Ratio
Forward P/E
P/B
Dividend Yield
Beta

Quantitative Metrics

MetricDFTXABCL
DCF Fair Value
DCF Upside
Piotroski F1/94/9
Altman Z
Beneish M
FCF Yield
Net Debt/EBITDA
ROIC-37.7%-12.4%
WACC
ROIC – WACC
Gross Margin
Net Margin-194.9%
Rev Growth YoY160.6%
Sharpe (1Y)
Max Drawdown 3Y
FCF Payout Ratio

DFTX Price

Loading chart...

ABCL Price

Loading chart...

ETF Exposure

DFTX found in:

XPH3.03%
VFMO0.08%
VTWO0.07%
VHT0.04%

ABCL found in:

GWX0.13%
SPDW0.01%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

DFTX vs ABCL: Head-to-Head Analysis

Definium Therapeutics, Inc. (DFTX) and AbCellera Biologics Inc. (ABCL) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, ABCL leads 4–1 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, DFTX generates a return on invested capital (ROIC) of -37.7% compared to ABCL's -12.4%. This suggests ABCL is more effective at deploying capital to generate shareholder returns.

DFTX appears in 4 ETFs tracked by SecuritiesDB, while ABCL appears in 2 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, DFTX or ABCL?

Our quantitative analysis compares DFTX and ABCL across nine fundamental dimensions. ABCL wins the Tale of the Tape 4–1. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are DFTX and ABCL correlated?

Correlation data is not yet available for this pair. Check back after both stocks have sufficient trading history.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.